0001548187-21-000076.txt : 20211217
0001548187-21-000076.hdr.sgml : 20211217
20211217170814
ACCESSION NUMBER: 0001548187-21-000076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211216
FILED AS OF DATE: 20211217
DATE AS OF CHANGE: 20211217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hauser Bradley
CENTRAL INDEX KEY: 0001662139
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38815
FILM NUMBER: 211502484
MAIL ADDRESS:
STREET 1: C/O ZELTIQ AESTHETICS, INC.
STREET 2: 4698 WILLOW ROAD, SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Soliton, Inc.
CENTRAL INDEX KEY: 0001548187
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 364729076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5304 ASHBROOK DRIVE
CITY: HOUSTON
STATE: TX
ZIP: 77081
BUSINESS PHONE: 832-661-3453
MAIL ADDRESS:
STREET 1: 5304 ASHBROOK DRIVE
CITY: HOUSTON
STATE: TX
ZIP: 77081
4
1
wf-form4_163977887874998.xml
FORM 4
X0306
4
2021-12-16
0
0001548187
Soliton, Inc.
SOLY
0001662139
Hauser Bradley
C/O SOLITON, INC. 5304 ASHBROOK DRIVE
HOUSTON
TX
77081
1
1
0
0
CEO and President
Stock option (right to buy)
1.75
2021-12-16
4
D
0
30000
D
2028-06-19
Common Stock
30000.0
0
D
Stock option (right to buy)
14.62
2021-12-16
4
D
0
15000
D
2029-06-27
Common Stock
15000.0
0
D
Stock option (right to buy)
12.94
2021-12-16
4
D
0
15000
D
2030-06-19
Common Stock
15000.0
0
D
Stock option (right to buy)
7.16
2021-12-16
4
D
0
350000
D
2030-10-30
Common Stock
350000.0
0
D
Restricted Stock Units
2021-12-16
4
D
0
200000
D
Common Stock
200000.0
0
D
Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding restricted stock unit, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration.
/s/ Bradley Hauser
2021-12-16